Would drugs used to treat Alzheimer's be useful to treat myeloma or amyloidosis?

Would drugs used to treat Alzheimer's be useful to treat myeloma or amyloidosis?
What are antibody drug conjugates?
What is Considered a Line of Therapy?
How can real world evidence lead to FDA label changes?
What is Off-label Use of a Drug?
How can real world data be used to guide treatment decision making?
What should patients know about bispecific antibody therapy and the risk for infection?
What is the definition of high-risk multiple myeloma (HRMM)?
What chromosomal abnormalities are considered high-risk cytogenetics markers?